According to the results obtained by our team on MMP-3 and MMP-7, they may appear to be useful as new biomarkers in the primary diagnosis of patients with early stage breast cancer (TNM stage I) and the most common subtypes—Luminal A and Luminal B HER2-negative. This evidence concerns the gene MMP7 and breast cancer.